University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland; Graduate School for Health Sciences, University of Bern, Switzerland.
University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland.
J Hepatol. 2021 Nov;75(5):1217-1227. doi: 10.1016/j.jhep.2021.07.025. Epub 2021 Jul 31.
In many countries worldwide, the burden of hepatocellular carcinoma (HCC) associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing. Preventive strategies are needed to counteract this trend. In this review, we provide an overview of the evidence on preventive strategies in NAFLD-associated HCC. We consider the impact of lifestyle factors such as weight loss, physical activity, smoking, dietary patterns and food items, including coffee and alcohol, on both HCC and NAFLD/NASH. Furthermore, evidence on chemopreventive treatments, including aspirin, antidiabetic treatments and statins is summarised. The role of adjuvant therapies for tertiary prevention of HCC is briefly reviewed.
在全球许多国家，与非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）相关的肝细胞癌（HCC）负担正在增加。需要采取预防策略来应对这一趋势。在这篇综述中，我们概述了预防 NAFLD 相关 HCC 的策略的证据。我们考虑了生活方式因素（如减肥、体力活动、吸烟、饮食模式和食物，包括咖啡和酒精）对 HCC 和 NAFLD/NASH 的影响。此外，还总结了包括阿司匹林、糖尿病治疗和他汀类药物在内的化学预防治疗的证据。简要回顾了辅助治疗 HCC 三级预防的作用。
